Optimal use of rifaximin in diverticular disease of the colon: use less for use better

I would like to thank Dr Marlicz and colleagues for their interesting comment about the current use of rifaximin in the management of diverticulosis and diverticular disease.1 In particular, all their concerns about the prolonged use of rifaximin are absolutely understandable and open the debate on how to use safely and effectively this non-absorbable antibiotic in the setting of diverticular disease. That is because the Guidelines cannot debate too much on a single drug and/or a single aspect about its use; thus, even debated in depth by very recent and rigorous Guidelines as the recent Fiesole Consensus,2 some aspect may remain underanalysed.